Figure 3.

The cellular levels of H3K9me2 predict clinical outcome in prostate and kidney cancers. Distribution of patients for the levels of H3K9me2 in cancer tissues from prostate (A) and kidney (C) are shown. The graphs represent the fraction of patients (y axis) with indicated levels of histone modifications as percent cell staining (x axis). For each cancer type, patients were first assigned to two groups based on the levels of H3K9me2, and then their clinical outcomes were compared (group 1, H3K9me2 >10%, black line; group 2, H3K9me2 ≤10%, red line). Kaplan-Meier plots are used to visualize the difference in outcome of the two groups in low-grade prostate (B) (log rank, P = 0.0043, n = 109) and all kidney (D) (log rank, P = 0.00092, n = 359) cancer patients. Tabulated in the insets is the distribution of the patients in each group according to grade.